Two commonly taken over-the-counter analgesics, aspirin and acetaminophen, were compared for: effect on total menstrual loss, effect on total days of menstruation, and effect in reduction of pain due to headaches and/or menstrual cramps. Drugs were administered during a 4-month study according to a double-blind format. During the first 2 months, subjects ingested no drugs whatsoever during their menstrual periods. During the second 2 months, subjects ingested aspirin, acetaminophen, or placebo at the rate of two 325-mg tablets every 4 h to total 8 tablets per day during the first 3 days of their menstrual periods. Statistical analysis of the first 2 periods compared to the last 2 showed no differences in total menstrual weights. The number of days of menstruation in the placebo group was significantly lower (p = 0.0137) than in its own control or in the other groups. Neither analgesic showed a significant reduction in pain due to headache or cramps, although acetaminophen appeared to be slightly more effective than aspirin in reducing menstrual cramps.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000299067 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France.
Clin Lymphoma Myeloma Leuk
October 2024
Department of Pharmacy, Paris Public Hospital at Home (HAD AP-HP), University Hospitals of Paris, Paris, France.
Article Synopsis
- - Acalabrutinib, a more advanced treatment for chronic lymphocytic leukemia, has a better safety profile than older drugs but lacks clear guidelines on managing its side effects, prompting a study to establish best practices.
- - A team of medical professionals across France found that hospital pharmacists should evaluate drug interactions before starting patients on acalabrutinib and advised against using it with certain medications that can increase risks of toxicity or reduce effectiveness.
- - The study highlighted the need for monitoring blood pressure during treatment, outlined protocols for managing procedures, and suggested headache management strategies, demonstrating the importance of teamwork in improving patient care while using acalabrutinib.
Drug risks associated with sarcopenia: a real-world and GWAS study.
BMC Pharmacol Toxicol
November 2024
The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, 214200, China.
Introduction: Drug-induced sarcopenia has not received adequate attention. Meanwhile, there is growing recognition of the importance of effective pharmacovigilance in evaluating the benefits and risks of medications.
Aims: The primary aim of this study is to investigate the potential association between drug use and sarcopenia through an analysis of adverse event reports from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and to evaluate the genetic factors contributing to drug-induced sarcopenia using summary-data-based Mendelian randomization (SMR).
2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache.
Ann Intern Med
December 2024
Aeromedical Consultation Service, U.S. Air Force School of Aerospace Medicine, Wright-Patterson Air Force Base, Ohio; Wright State University Boonshoft School of Medicine, Dayton, Ohio; and Uniformed Services University F. Edward Hebert School of Medicine, Bethesda, Maryland (A.W.F.).
Description: Headache medicine and therapeutics evidence have been rapidly expanding and evolving since the 2020 U.S. Department of Veterans Affairs (VA) and U.
View Article and Find Full Text PDFRegular Nonsteroidal Anti-Inflammatory Drug Use Increases Stress Fracture Risk in the General Population: A Retrospective Case-Control Study.
Adv Orthop
October 2024
Department of Orthopaedic Surgery, Thomas Jefferson University, Philadelphia 19107, PA, USA.
Previous studies have shown that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with increased stress fracture risk. This phenomenon has been studied predominantly in high-activity individuals, so data regarding the general population are limited despite the substantial economic and resource burden of stress fracture injuries within the general US population. Furthermore, our preclinical studies demonstrate that regular use of NSAIDs also diminishes the intrinsic ability of bone to resist fracture.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!